The Financial Express1h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
pharmaphorum21d
AstraZeneca, Honeywell partner to address climate change with new inhaler tech
UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...
Pharmaceutical Technology2d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Nasdaq28d
Is AstraZeneca Stock a Buy?
That said, many drugmakers are working on oral GLP-1 medications or weight-loss drugs of other kinds. AstraZeneca still has a long way to go before its candidates are approved, if they get that far.